Home - Products - Cell Cycle/DNA Damage - ATM/ATR - Arg-Gly-Asp TFA

Arg-Gly-Asp TFA

CAS No. ——

Arg-Gly-Asp TFA ( —— )

Catalog No. M19317 CAS No. ——

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	58	Get Quote
10MG	100	Get Quote
100MG	Get Quote	Get Quote
200MG	Get Quote	Get Quote
500MG	Get Quote	Get Quote
1G	Get Quote	Get Quote

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Arg-Gly-Asp TFA
Note

Research use only, not for human use.
Brief Description

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
Description

RGD Trifluoroacetate is a tripeptide that effectively triggers cell adhesion, addresses certain cell lines and elicits specific cell responses; binds to integrins.
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Cell Cycle/DNA Damage
Target

ATM/ATR
Recptor

Integrin
Research Area

——
Indication

——

Chemical Information

CAS Number

——
Formula Weight

460.36
Molecular Formula

C14H23F3N6O8
Purity

>98% (HPLC)
Solubility

——
SMILES

OC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N.FC(F)(F)C(=O)O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Hersel U, et al. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials. 2003 Nov;24(24):4385-415.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

VE-821

A potent, selective and ATP-competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM; shows excellent selectivity for ATR over the related PIKKs ATM, DNA-PK, mTOR and PI3K.
Lartesertib

Lartesertib (ATM Inhibitor-5) is an inhibitor of serine/threonine protein kinase ATM with potential anticancer activity for the study of lung cancer.
AZD1390

AZD1390 (AZD-1390) is a novel potent, selective, orally available and CNS penetrant ATM inhibitor with IC50 of 0.78 nM.Brain Cancer,Phase 1 Clinical

Sign In Join Free